Asia IVD Market Entry Is No Longer Just About Finding a Distributor

For many international IVD manufacturers, the traditional Asia strategy was simple: appoint a distributor, ship products and wait for sales. That approach is becoming less effective. Across Asia, success now depends on a more disciplined combination of regulatory planning, channel selection, technical support, market education and long-term distributor management.

A larger market, but not an easier one

Asia remains one of the most attractive regions for in vitro diagnostics. Demand is supported by rising healthcare investment, broader laboratory access, infectious disease testing, chronic disease management, cancer screening, women’s health, fertility, autoimmune testing and the gradual expansion of molecular and immunoassay platforms beyond top-tier hospitals.

However, market growth does not automatically translate into commercial success. Asia is not one market. China, India, Japan, South Korea, Singapore, Thailand, Vietnam, Indonesia, Malaysia and the Philippines each have different regulatory systems, reimbursement conditions, hospital purchasing habits, private laboratory structures and distributor capabilities.

The distributor question is becoming more strategic

In the past, many manufacturers selected distributors based mainly on product coverage, existing customer lists or willingness to register the product. Today, that is not enough. A distributor may have many brands but limited focus. Another may have good regulatory experience but weak technical support. Some may be strong in capital cities but almost invisible in secondary cities.

The most important question is no longer simply, “Who can distribute this product?” The better question is, “Who can build this product category in this country?”

This requires a clear view of target customers, clinical positioning, competitive alternatives, pricing corridor, registration pathway, application support, service response and the manufacturer’s willingness to invest in early market development.

Regulatory planning must come before commercial enthusiasm

Many market entry projects fail because the commercial discussion runs ahead of the regulatory reality. A product may look attractive, but the registration timeline, local representative requirement, documentation quality, product classification, labeling, stability data and post-market obligations can change the actual business case.

Service and application support are now part of market access

In Asia, a product with good performance can still fail if the local support model is weak. Laboratories expect fast response, user training, troubleshooting, installation support and clear communication. For instruments, the quality of local service can decide whether a customer repeats orders or quietly moves to another supplier.

This is especially important for CLIA, molecular diagnostics, specialty immunoassays, microbiology, laboratory water systems and other workflow-dependent products. A distributor that only sells but cannot support the product may create short-term access but long-term damage to the brand.

What manufacturers should do differently

A more effective Asia strategy starts with segmentation. Not every country should be entered at the same time. Not every distributor should be given a broad portfolio. Not every product should be registered immediately. Manufacturers should prioritize countries where the clinical need, competitive gap, registration feasibility and distributor capability align.

The next step is distributor due diligence. This should include ownership structure, current product lines, territory coverage, technical team size, hospital and private lab access, registration experience, service capability and willingness to execute a business development plan rather than simply hold a distribution agreement.

Finally, manufacturers need active regional management. Asia cannot be managed only through occasional emails and price lists. It requires structured follow-up, country-level planning, training, lead generation, congress participation, reference-site building and realistic performance review.